ClinicalTrials.gg

Program

PA9159

A development code. Also written as “PA9159 nasal spray solution, 80 μg one day treatment”, “PA9159 Metered-Dose Inhaler, 120 μg per day for 28 days” and “PA9159 nasal spray solution, 160 μg one day treatment”.

Its studies are mostly in Asthma · Rhinitis, Allergic · Rhinitis, Allergic, Seasonal, led by Anhui Palo Alto Pharmaceuticals.

Furthest: phase 2, since Feb 1, 20226 company-led studies, 2 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Anhui Palo Alto Pharmaceuticals62 open or runningphase 2since Feb 1, 2022Sep 28, 2021none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 28, 2021First study: phase 1 study in Rhinitis, AllergicFirst studyNCT05170763 · 60 enrolled · China
  2. Feb 1, 2022Phase 2 study in Rhinitis, AllergicNCT05234580 · 204 enrolled · China
  3. Mar 12, 2025Phase 1 study in AsthmaNCT06916273 · 40 enrolled · China
  4. Dec 23, 2025Phase 1 study in Rhinitis, AllergicNCT07345442 · 36 enrolled · China
  5. Dec 23, 20252 phase 2 studies in AsthmaNCT07326995, NCT07324707

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 6 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07324707Asthma · China2RecruitingMar 202630
NCT07345442Rhinitis, Allergic · China1CompletedJun 9, 202536
NCT07326995Asthma · China2RecruitingFeb 202660
NCT06916273Asthma · China1CompletedSep 12, 202440
NCT05234580Rhinitis, Allergic · China2CompletedOct 10, 2022204
NCT05170763Rhinitis, Allergic · China1CompletedJan 5, 202260

How it is read

Names in the registry

  • “PA9159 nasal spray solution, 80 μg one day treatment”, 2 entries
  • “PA9159 Metered-Dose Inhaler, 120 μg per day for 28 days”, 2 entries
  • “PA9159 nasal spray solution, 160 μg one day treatment”, 1 entry
  • “PA9159 nasal spray solution, 320 μg one day treatment”, 1 entry
  • “PA9159 nasal spray solution, 80 μg 7-day treatment”, 1 entry

Codes read as this program: PA9159.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.